Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma

Exclusion Criteria

• •Lung diseases other than mild allergic asthma
• •History or symptoms of cardiovascular disease, significant neurologic disease, and/or clinically significant autoimmune disease
• •Chronic use of asthma medications other than short or intermediate beta-agonists or ipratropium
• •Use of tobacco products within one year starting study or smoking history \>10 pack years
• •If female, pregnant or lactating or have positive pregnancy test at screening